Incidence and risk of hepatic toxicities with PD-1 inhibitors in cancer patients: a meta-analysis
Xi Zhang,1 Yuge Ran,1 Kunjie Wang,2 Yuanxue Zhu,2 Jinghua Li3 1Department of Radiation Oncology, 2Department of Medical Oncology, 3Department of Hepatobiliary Surgery, Affiliated Hospital of Hebei University, Baoding, People’s Republic of China Purpose: Anti-programmed cell death receptor-...
Saved in:
Main Authors: | Zhang X (Author), Ran Y (Author), Wang K (Author), Zhu Y (Author), Li J (Author) |
---|---|
Format: | Book |
Published: |
Dove Medical Press,
2016-09-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Inhibitors of the PD-1/PD-L1 axis for the treatment of head and neck cancer: current status and future perspectives
by: Ran X, et al.
Published: (2017) -
Efficacy of PD-1/PD-L1 inhibitors in ovarian cancer: a single-arm meta-analysis
by: Jue Zhu, et al.
Published: (2021) -
Editorial: Toxicity mechanism and clinical features of PD-1/PD-l1 inhibitors in treatment of cancer, volume II
by: Chuqi Lei, et al.
Published: (2023) -
Editorial: Toxicity Mechanism and Clinical Features of PD-1/PD-L1 Inhibitors in Treatment of Cancer, Volume I
by: Xiangyi Kong, et al.
Published: (2022) -
Risk of hematologic toxicities with programmed cell death-1 inhibitors in cancer patients: a meta-analysis of current studies
by: Sui JD, et al.
Published: (2018)